Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLG-FT101
- Development stage
- Preclinical
- Lead developer
- Porosome Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
TLG-FT101 is an investigational porosome nanoparticle therapy being developed by Porosome Therapeutics for the treatment of tumors. The therapy is based on the discovery of the porosome, which is the universal secretory portal in cells responsible for the precision release of intra-cellular products. TLG-FT101 utilizes proprietary porosome-based nanoparticle technology to deliver therapeutic agents or modulate cellular secretion within the tumor microenvironment. As of 2024, the candidate is in mid-stage development, aiming to provide a more targeted and efficient delivery mechanism compared to traditional nanoparticle platforms.
Beyond the preview
Go deeper on TLG-FT101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLG-FT101.